AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04137640
Drug: palbociclib combined with letrozole
RxNorm normalized name: Palbociclib
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Endocrine group will receive palbociclib combined with letrozole: palbociclib (Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; license number: H20180040) 125 mg/d, every 28 days as a cycle (medication for 3 consecutive weeks and withdrawal for 1 week); letrozole (Novartis Pharma Schweiz AG, Stein, Switzerland; license number: H20140149) 2.5 mg/d, for 6 consecutive months.
Trial: NCT05666869
Drug: Esketamine perfusion
RxNorm normalized name: esketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Analgesic dose of ESKETAMINE via a 30 minutes.intravenous perfusion
Trial: NCT06209268
Drug: Paricalcitol injection
RxNorm normalized name: paricalcitol Injection
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 μg intravenous paricalcitol (1 mL) per day in five consecutive days
Trial: NCT05623319
Drug: Pembrolizumab/Olaparib
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive pembrolizumab 200 mg 1q21 and chemotherapy -platinum compound (cisplatin 75 mg/m2 or carboplatin area under the curve of 5 mg per milliliter per minute) 1q21 plus etoposide 100 mg/m2 1-3q21- for 4 cycles (Induction Phase). In case of responsive or stable disease, patients will receive pembrolizumab 200 mg 1q21 plus olaparib 300 mg twice daily until progression (Maintenance Phase) or up to a maximum of 35 cycles.
Trial: NCT06503263
Drug: Zanubrutinib plus Lenalidomide as Maintenance Therapy
RxNorm normalized name: Zanubrutinib
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients were treated by Zanubrutinib(160mg po bid d1-28) plus Lenalidomide(25mg po qd d1-14) as maintenance therapy until 2 years post chemotherpay
Trial: NCT06188637
Drug: Ozanimod Oral Capsule
RxNorm normalized name: ozanimod Oral Capsule
DrugBank: Ozanimod (DB12612)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: open label ozanimod
Trial: NCT06233942
Drug: BG-C9074
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered by intravenous infusion
Trial: NCT06233942
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered by intravenous infusion
Trial: NCT06234761
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patient who start to take dupilumab will be followed. This study is only observational
Trial: NCT06140589
Drug: Cadonilimab
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intravenous dose of Cadonilimab was 10mg/kg, and every 3 weeks was a course of treatment; Or 6mg/kg, every 2 weeks for a course of treatment
Trial: NCT04932564
Drug: Leflunomide tablet
RxNorm normalized name: Leflunomide Tablets
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leflunomide will be given at standard dose (100 mg OD x 3 days followed by 20 mg OD) in adults and weight based dose in children.~The dosing for children will be as follows:~1. \<20 kg - 100 mg x 1 day followed by 10 mg every alternate day~2. 20-40 kg - 100 mg x 2 days, followed by 10 mg daily~3. \>40 kg - Usual adult dose.~This is scheduled to be continued for 1 year from the time of attaining complete response of musculoskeletal GVHD.
Trial: NCT05697328
Drug: Pseudoephedrine Pill
RxNorm normalized name: pseudoephedrine Pill
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One-time 60mg dose given orally between 45-120 minutes prior to hyperbaric oxygen therapy
Trial: NCT05136326
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 75 mg/sqm p.o. 5 days/week for 5 weeks
Trial: NCT00004219
Drug: granisetron hydrochloride
RxNorm normalized name: Granisetron Hydrochloride
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004219
Drug: lerisetron
RxNorm normalized name: Lerisetron
DrugBank: Lerisetron (DB12964)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05076006
Drug: PF-06700841
RxNorm normalized name: PF-06700841
DrugBank: PF-06700841 (DB15003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active study drug
Trial: NCT05614817
Drug: CBP-201
RxNorm normalized name: CBPC
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CBP-201 subcutaneous(SC) injection
Trial: NCT06553937
Drug: Macitentan and Tadalafil
RxNorm normalized name: macitentan and tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet of Macitentan and Tadalafil film-coated tablets 10 mg/40 mg
Trial: NCT05494385
Drug: Preoperative Gabapentin/Postoperative Placebo
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperatively, this group will receive scheduled acetaminophen and ibuprofen every 6 hours, in addition to placebo every 12 hours. The placebo is encapsulated to appear identical to the active drug. This group will have oxycodone 5 mg every 6 hours as needed for pain.
Trial: NCT05494385
Drug: Preoperative Gabapentin/Postoperative Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperatively, this group will receive scheduled acetaminophen and ibuprofen every 6 hours, in addition to gabapentin every 12 hours. The gabapentin is encapsulated to appear identical to the placebo. This group will have oxycodone 5 mg every 6 hours as needed for pain.
Trial: NCT05569408
Drug: EVUSHELD
RxNorm normalized name: Evusheld
DrugBank: Cilgavimab (DB16393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tixagevimab (AZD8895) and cilgavimab (AZD1061)
Trial: NCT06116045
Drug: BZ371A 7.5 mg (1.5 ml)
DrugBank: BZ371A (DB18101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg gel
Trial: NCT06116045
Drug: BZ371A 5.0 mg (1.0 ml)
DrugBank: BZ371A (DB18101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg gel
Trial: NCT06116045
Drug: BZ371A 2.5 mg (0.5 ml)
DrugBank: BZ371A (DB18101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg gel
Trial: NCT04381130
Drug: EF-009
RxNorm normalized name: Klor-Con/EF
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who meet the eligibility criteria will have completed following evaluations and assessments before receiving treatment: a) review of medical and medication history; b) physical examination, vital signs and documentation of ECOG; c) ECG; d) routine serum biochemical, hematologic, urine pregnancy (if applicable) and urine laboratory assessments; and e) evaluation of European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 score.~On Day 0, subjects will undergo EF-009 wafer implantation via laparoscopy
Trial: NCT05038007
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As prior described
Trial: NCT05038007
Drug: Bupivacaine Hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As prior described
Trial: NCT06076837
Drug: Botensilimab
RxNorm normalized name: Botensilimab
DrugBank: Botensilimab (DB16651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an Fc-engineered anti-CTLA-4 (cytotoxic T-lymphocyte antigen 4) monoclonal antibody
Trial: NCT06076837
Drug: Balstilimab
RxNorm normalized name: Balstilimab
DrugBank: Balstilimab (DB15676)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a human monoclonal immunoglobulin (Ig) G4 (IgG4) antibody, designed to block programmed cell death protein (PD-1) binding by PD-L1 and PD-L2
Trial: NCT06076837
Drug: Chloroquine Phosphate
RxNorm normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: an antimalarial agent, that is being used in this patient population to sensitize cancer cells to chemotherapy and leads to anticancer effects through inhibiting autophagy
Trial: NCT05913232
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ophthalmic solution
Trial: NCT05227196
Drug: Semaglutide D Dose 1
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet given orally
Trial: NCT05227196
Drug: Semaglutide D Dose 2
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet given orally
Trial: NCT05227196
Drug: Semaglutide D Dose 3
RxNorm normalized name: semaglutide 3 MG
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet given orally
Trial: NCT05227196
Drug: Semaglutide Dose 4
RxNorm normalized name: semaglutide 4 MG
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet given orally
Trial: NCT05227196
Drug: Semaglutide Dose 5
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet given orally
Trial: NCT05227196
Drug: Semaglutide Dose 6
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet given orally
Trial: NCT05306899
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus of IV Ketamine 1 mg.kg-1 (= 0.1 ml.kg-1) followed by Infusion of Ketamine 1 mg.kg-1.hour-1 (= 0.5 mL.kg-1.hour-1) for 6 hours. All patients will receive IV midazolam 0.04 mg.kg-1 (maximum 3 mg) and subsequently 0.01-0.02 mg.kg-1 every hour to keep participants in a sedated but arousable state (Ramsay Sedation Scale score 3 or 4) to blind the participants and assessors to group allocation. Ondansetron 8 mg and 8 mg of dexamethasone will be administered to prevent nausea, 5000 units of heparin will be given subcutaneously to prevent thrombo-embolic events.
Trial: NCT06076837
Drug: Nab paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: microtubule inhibitor indicated for the treatment of Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine
Trial: NCT06076837
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: a nucleoside metabolic inhibitor indicated as a single agent for the treatment of pancreatic cancer
Trial: NCT06076837
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: platinum-based drug indicated for the treatment of advanced cancers
Trial: NCT05891379
Drug: Inebilizumab
RxNorm normalized name: INEBILIZUMAB
DrugBank: Inebilizumab (DB12530)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Inebilizumab: 300mg IV on Day1 and Day 15. The first dose of inelizumab is given during IVMP.
Trial: NCT05937295
Drug: Fusion-VAC-XS15
RxNorm normalized name: Duo Fusion
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FusionVAC-22 peptide will be administered subcutaneously (s.c.) adjuvanted with the Toll-like receptor 1/2 ligand XS15 (50 μg) emulsified in Montanide ISA 51 VG (1:1).~Vaccination will take place every 4 weeks at the beginning of Cycle 1 and 2. A total of two vaccinations are planned.~After 11 months a booster vaccination can be applied depending on T-cell responses.~Immune checkpoint inhibition (ICI):~Atezolizumab (TecentriqTM, Roche Pharma AG) is a humanized immunoglobulin (Ig) G1 monoclonal antibody that targets PD-L1 and will be applied intravenously (i.v.).~The anti-PD-L1 antibody Atezolizumab (TecentriqTM) 1680 mg will be applied every 4 weeks as a 30-minute infusion (60-minute first dose) starting on day 15 after the first vaccination. Anti-PD-L1 treatment will be continued after the end of vaccination phase throughout the complete study period until End of Treatment (EOT) or until disease progression or other reasons for study termination.
Trial: NCT05655299
Drug: VTX958 Dose C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose C
Trial: NCT05655299
Drug: VTX958 Dose D
RxNorm normalized name: D
DrugBank: Rosomidnar (DB17154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose D
Trial: NCT04708366
Drug: MoviPrep
RxNorm normalized name: MoviPrep
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be randomly assigned (1:1:1) to receive 1L PEG (PLENVU; Norgine, Amsterdam, Netherlands), administered as a 2-day evening/morning split-dosing, or the 2L PEG + ascorbate preparation (2LPEG - MOVIPREP; Norgine), or the 4L PEG (SELG-ESSE; Alfasigma Bologna, Italy), both administered as a 2-day evening/morning split-dosing regimen.
Trial: NCT04446039
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for depression
Trial: NCT04446039
Drug: Paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for depression
Trial: NCT04446039
Drug: Mirtazapine
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for depression
Trial: NCT04446039
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for depression
Trial: NCT04446039
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for depression
Trial: NCT04446039
Drug: Venlafaxine
RxNorm normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for depression
Trial: NCT04446039
Drug: Tianeptine
RxNorm normalized name: tianeptine
DrugBank: Tianeptine (DB09289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment for depression
Trial: NCT04446039
Drug: Vortioxetine
RxNorm normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment for depression
Trial: NCT04446039
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for depression
Trial: NCT05005429
Drug: Bintrafusp alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bintrafusp alfa (M7824) is a bifunctional fusion protein composed of the extracellular domain of the transforming growth factor β (TGF-β) receptor II (a TGF-β trap) fused to a human immunoglobulin G1 antibody blocking programmed death-ligand 1 (PD-L1).~Day 1 of week 1 of treatment will start within 1-5 days from enrollment. Cycles will be administered every 2 weeks (±3 days) until progression or other reason to discontinue. If a pseudoprogression is suspected patient is allowed to continue treatment until loss of clinical benefit as judged by principal investigator and after the permission from the trial chair is granted.~On Day 1 of each cycle (QW2), all eligible patients will receive:~Bintrafusp alfa (M7824): 1200mg, IV infusion over 60 minutes Current experience revealed that IRRs to bintrafusp alfa occur seldomly and are generally mild to moderate in severity. Therefore, administration of a premedication is generally not required.
Trial: NCT06651541
Drug: BZ371A
RxNorm normalized name: BZ371A
DrugBank: BZ371A (DB18101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation with the active ingredient
Trial: NCT05897658
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets
Trial: NCT05023551
Drug: DSP-0390
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DSP-0390 administered orally
Trial: NCT06141226
Drug: TQB2450 +Anlotinib+Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on the surface of T cells, restoring T cell activity and enhancing immune response. It has the potential to treat various types of tumors.~Anlotinib is a multi target receptor tyrosine kinase (RTK) inhibitor. It can inhibit VEGFR1, VEGFR2, VEGFR3, c-Kit, PDGFR β Activity.~Docetaxel is a taxane based anti-tumor drug.
Trial: NCT06141226
Drug: TQB2450 +Androtinib Placebo+Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand 1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on the surface of T cells, restoring T cell activity and enhancing immune response. It has the potential to treat various types of tumors.~Androtinib Placebo Docetaxel is a taxane based anti-tumor drug.
Trial: NCT06342037
Drug: Tiragolumab
RxNorm normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg every 3 weeks (Q3W)
Trial: NCT06342037
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1200mg every 3 weeks (Q3W)
Trial: NCT06342037
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1 mg/kg, maximum of 4 cycles
Trial: NCT05562999
Drug: Rocuronium Bromide
RxNorm normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate NMB (TOF 1-2)
Trial: NCT05562999
Drug: Rocuronium Bromide
RxNorm normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deep NMB (PTC 1-2)
Trial: NCT05030129
Drug: 5-Hydroxytryptophan
RxNorm normalized name: 5-Hydroxytryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-HTP will be over-encapsulated in identical size 00 capsules. During the 5-HTP Treatment Period (Period 3) and 5-HTP/EM Treatment Period (Period 2), subjects will take 1 capsule of 5-HTP 3 times per day.
Trial: NCT05030129
Drug: Ergoloid Mesylates
RxNorm normalized name: Ergoloid Mesylates
DrugBank: Ergoloid mesylate (DB01049)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ergoloid mesylates 1 mg will be mixed with methyl cellulose and placed in a size 00 capsule. During the EM Treatment Period (Period 1) and 5-HTP/EM Treatment Period (Period 2), subjects will take 1 capsule of EM 3 times per day.
Trial: NCT05030129
Drug: Matching placebo for Ergoloid mesylates
RxNorm normalized name: Ergoloid Mesylates
DrugBank: Ergoloid mesylate (DB01049)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Matching placebo for Ergoloid mesylates will be ascorbic acid powder in identical size 00 capsules. During the 5-HTP Treatment Period (Period 3) and Placebo Treatment Period (Period 4), subjects will take 1 capsule of matching placebo for EM 3 times per day.
Trial: NCT05030129
Drug: Matching placebo for 5-Hydroxytryptophan
DrugBank: Tryptophan (DB00150)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Matching placebo for 5-Hydroxytryptophan will be ascorbic acid powder in identical size 00 capsules. During the EM Treatment Period (Period 2) and Placebo Treatment Period (Period 4), subjects will take 1 capsule of matching placebo for 5-HTP 3 times per day.
Trial: NCT05643495
Drug: VX-864
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration.
Trial: NCT06654804
Drug: Perflutren lipid
RxNorm normalized name: perflutren lipid microspheres
DrugBank: Perflutren (DB00556)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus injection of contrast during spinal decompression surgery for the treatment of traumatic spinal cord injury. Ultrasound imaging will then be used to collect images of the spinal cord injury to record perfusion, inflow and washout.
Trial: NCT06587620
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Start IV infusion of a loading dose of tranexamic acid 10 mg/kg completed to 50 ml saline over 10 min before induction of anesthesia. IV infusion of tranexamic acid at a dose of 1 mg/kg/h immediately after induction till 15 min before the end of surgery.
Trial: NCT06587620
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Start IV infusion of a loading dose of dexmedetomidine 1ug/kg completed to 50 ml saline over 10 min before induction of anesthesia. IV infusion of dexmedetomidine 0.3-0.7 µg/kg/h immediately after induction to maintain Mean Arterial Pressure (MAP) between 60-70 mmHg till 15 min before the end of surgery.
Trial: NCT03651752
Drug: Diphenylcyclopropenone (DPCP) Ointment
RxNorm normalized name: Diphenylcyclopropenone
DrugBank: Diphencyprone (DB12173)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects will be administered a sensitization dose of 0.05 mL 0.4% DPCP ointment formulation topically in the inner aspect of the upper right arm at Day -16, and 0.05 mL of four concentrations (0.1, .05, 0.01, 0.005%), prepared through dilutions in the ointment vehicle, topically on the inner aspect of the left thigh at Day -2. The weakest strength that may cause a minimal reaction (DTH skin reaction score of 1+) after two days will be chosen, and 0.75-1 g of that concentration will be applied to the scalp starting at Week 1 and administered subsequently twice a week for 18 weeks
Trial: NCT06169410
Drug: nab-paclitaxel, lobaplatin, and S-1 combined with ramucirumab
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients in Experimental group will be given ramucirumab (8mg/kg) by intravenous drip on the first day of each cycle, 3 weeks a cycle.
Trial: NCT06035068
Drug: Indocyanine green
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Indocyanine green (ICG) is a fluorescent dye that has been used for the imaging of cancers in the body for more than 30 years.